DJIA 16,677.90 216.58 1.32%
NASDAQ 4,452.79 69.95 1.60%
S&P 500 1,950.82 23.71 1.23%
market minute promo

Gilead Sciences (NASDAQ: GILD)

107.18 1.09 (1.03%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $107.18 1.03%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $106.64
Previous Close $106.09
Daily Range $105.50 - $108.18
52-Week Range $63.50 - $110.64
Market Cap $162.0B
P/E Ratio 23.89
Dividend (Yield) $0.00 (0.0%)
Volume 13,853,394
Average Daily Volume 14,840,098
Current FY EPS $7.26

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

Why Regulus Therapeutics Inc. Stock More Than Doubled

Regulus Therapeutics is today's best biotech stock as its shares more than doubled following the release of positive interim hepatitis C drug data.

Regulus Therapeutics' RG-101 Poses Liver Cancer Risk

Gilead's Hep C Dream Drug Faces Demanding Investors

Regulus Gets Seat at Hep C Table With Today's Impressive Drug Results

Is Johnson & Johnson's Worst Nightmare Becoming Reality?

Johnson & Johnson has become a growth story on the back of strong pharmaceutical sales over the past two quarters. This trend looks like it is about to change with the approval of a rival's game-changing drug.

Speculating on Achillion's Boom-or-Bust Hep C Drug Study Results

Priceline Is On Sale

Gilead Sciences: Pricing, Politics And Profits

Gilead Sciences: Clear The Dockets And Settle With Merck Already

3 Drugs Critical to Johnson & Johnson's Future

Johnson & Johnson faces new threats to top selling drugs this year, but these three drugs may blunt the risk.

See More GILD News...

GILD's Top Competitors

GILD $107.18 (1.03%)
Current stock: GILD
AMGN $147.25 (2.51%)
Current stock: AMGN
CELG $100.40 (5.95%)
Current stock: CELG
$0.00 (0.00%)
Current stock: